MoneyTreeTM: Reaching for growth
US venture capital funding for the life sciences sector has lost some of the momentum gained during the first half of the year but remains on track to outpace 2010. Third-quarter 2011 funding for the sector, which includes biotechnology and medical devices, fell 18% quarter over quarter, according to the MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), based on data provided by Thomson Reuters. Venture capitalists invested $1.8 billion in 170 life sciences deals, reflecting a continued interest in venture investment but the lowest number of deals since the first quarter of 2009.
Look for papers, articles, and case studies. See all thought leadership.